Johnson & Johnson's Earnings Made Easy

JNJ Earnings beat expectations, but is trouble lurking beneath the headlines?

Dave Williamson
Dave Williamson and Michael Douglass
Apr 20, 2014 at 8:12AM
Health Care

Johnson & Johnson's (NYSE:JNJ) recently reported earnings and the massive health-care conglomerate posted another strong performance. Revenue grew 3% and earnings popped 8%, beating analysts' expectations. But is there trouble lurking beneath the rosy headlines?

The pharma segment, possibly the industry's strongest, posted its sixth quarter of double-digit growth out of the past seven. Those 11% gains help offset weakness in the consumer segment, which declined 1%, and a slightly disappointing showing of 2% growth from medical devices.

In this episode of Market Check-Up, The Motley Fool's health care-focused investing show, analysts David Williamson and Michael Douglass break down J&J's quarter, giving highlights and lowlights of each division's performance. This includes the launch of Michael's newest favorite medical device, the Thermacool Smarttouch Catheter, as well as the company's asset sales. Watch and find out how investors should react to this news and what Johnson & Johnson needs to do to keep up the positive earnings surprises.